ABIONYX Pharma SA
EPA:ABNX.PA
1.35 (EUR) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4.64 | 5.252 | 0.675 | 0 | 0 | 0.174 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 3.499 | 4.616 | 0.416 | 0.08 | 0.072 | 0 | 0.043 | 0.053 | 0.055 | 0 | 0 |
| Gross Profit
| 1.141 | 0.636 | 0.259 | -0.08 | -0.072 | 0.174 | -0.043 | -0.053 | -0.055 | 0 | 0 |
| Gross Profit Ratio
| 0.246 | 0.121 | 0.384 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 2.902 | 1.107 | 4.928 | 1.698 | 0.744 | 4.295 | 4.899 | 17.004 | 12.561 | 2.136 | 5.612 |
| General & Administrative Expenses
| 1.106 | 1.321 | 0.586 | 0.562 | 1.125 | 1.19 | 1.61 | 1.88 | 1.25 | 1.561 | 1.405 |
| Selling & Marketing Expenses
| 2.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.132 | 1.321 | 0.586 | 0.562 | 1.125 | 1.19 | 1.61 | 1.88 | 1.25 | 1.561 | 1.405 |
| Other Expenses
| 1.159 | 2.317 | 0.697 | 0.708 | 0.655 | 1.741 | 0.128 | 5.151 | 1.663 | 0 | 0 |
| Operating Expenses
| 6.034 | 4.745 | 6.211 | 2.968 | 2.524 | 7.226 | 6.637 | 24.035 | 15.474 | 6.069 | 9.808 |
| Operating Income
| -4.893 | -4.109 | -5.952 | -2.968 | 2.238 | -7.052 | -6.637 | -24.035 | -15.474 | -6.069 | -9.808 |
| Operating Income Ratio
| -1.055 | -0.782 | -8.818 | 0 | 0 | -40.529 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.009 | -0.097 | 0.13 | 1.082 | -0.35 | 0.748 | 1.661 | -0.841 | -1.164 | -0.531 | 2.108 |
| Income Before Tax
| -4.902 | -4.206 | -5.822 | -1.886 | 1.888 | -6.304 | -4.976 | -24.876 | -16.638 | -6.6 | -7.7 |
| Income Before Tax Ratio
| -1.056 | -0.801 | -8.625 | 0 | 0 | -36.23 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.384 | 0.097 | 0.008 | -0.617 | 0.038 | 0.001 | 0.002 | -0.005 | 0.053 | -0.037 | 0.042 |
| Net Income
| -3.518 | -4.303 | -5.83 | -1.886 | 1.849 | -6.305 | -4.978 | -24.871 | -16.638 | -6.563 | -7.742 |
| Net Income Ratio
| -0.758 | -0.819 | -8.637 | 0 | 0 | -36.236 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.12 | -0.15 | -0.23 | -0.084 | 0.09 | -0.32 | -0.27 | -1.39 | -1 | -0.5 | -0.59 |
| EPS Diluted
| -0.12 | -0.15 | -0.23 | -0.084 | 0.088 | -0.32 | -0.26 | -1.28 | -1 | -0.5 | -0.59 |
| EBITDA
| -5.053 | -4.01 | -5.695 | -1.864 | 2.251 | -5.549 | -4.766 | -23.571 | -15.365 | -5.333 | -7.334 |
| EBITDA Ratio
| -1.089 | -0.764 | -8.437 | 0 | 0 | -31.891 | 0 | 0 | 0 | 0 | 0 |